Clinical trial for Multiple Myeloma
Official title A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
ClinicalTrials.gov ID: NCT06500884
What this study is testing
What is Talquetamab?
Talquetamab is an investigational subcutaneous medicine being studied as a potential treatment for multiple myeloma. It is designed to bind both CD3 on T cells and GPRC5D on myeloma cells, directing the immune system to attack the cancer cells.
Also referred to as CD3xGPRC5D.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether preventive treatments can reduce taste changes caused by talquetamab and ramantamig.
- Who it's for
- You may be able to join if you have multiple myeloma and are planned to receive talquetamab or ramantamig.
- What's involved
- You would take a preventive medicine while you receive the cancer drug. You will report any taste changes and attend study visits.
- Time commitment
- You will stay in the study for the preventive treatment period and attend scheduled check‑ins.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Multiple myeloma (MM) according to IMWG diagnostic criteria
- Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening.
- Be willing and able to adhere to the lifestyle restrictions specified in the protocol
You likely can't join if
- Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients
- Stroke, transient ischemic attack, or seizure within 6 months prior to screening
- Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction
- Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully...
- A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization.
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- New York, New York, United States
- Rochester, New York, United States
- Durham, North Carolina, United States
- Cleveland, Ohio, United States
- Richmond, Virginia, United States
- Seattle, Washington, United States
- Brasília, Brazil
- Caxias do Sul, Brazil
- Curitiba, Brazil
- Salvador, Brazil
- São Paulo, Brazil
- Amsterdam, Netherlands
- Dordrecht, Netherlands
- Rotterdam, Netherlands
- San Juan, Puerto Rico
- Seoul, South Korea
- Badalona, Spain
+ 12 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States; Denver, Colorado, United States; New Haven, Connecticut, United States; New York, New York, United States; Rochester, New York, United States; Durham, North Carolina, United States and 26 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.